The treatment and outcome prediction analysis of pediatric acquired severe aplastic anemia
Yi-Xian Li1, Yun Chen2, Jun-Bin Huang1
1Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University Shenzhen, Guangdong, PR China.
Insights
Predicting treatment response in pediatric severe aplastic anemia (SAA) is key. This review explores factors influencing immunosuppressive therapy (IST) and stem cell transplant (SCT) outcomes for better clinical decisions.
Area of Science:
- Hematology
- Pediatric Oncology
- Immunology
Background:
- Pediatric acquired severe aplastic anemia (SAA) is a serious non-malignant hematological disorder with complex treatment challenges.
- Current treatments like immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) have limitations including long duration, high costs, and variable survival outcomes.
Purpose of the Study:
- To review recent advancements in treating pediatric SAA.
- To identify key predictors influencing the efficacy of IST and haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
- To support clinical decision-making by discussing factors affecting treatment outcomes in pediatric SAA.
Main Methods:
- Literature review summarizing recent studies on pediatric SAA treatment.
- Analysis of predictive factors for IST and haplo-HSCT efficacy.
- Discussion of transplantation-based scoring systems for prognosis.
Main Results:
- Recent studies have identified predictive factors for IST and haplo-HSCT in pediatric SAA.
- Development and use of transplantation-based scoring systems are increasing for prognosis evaluation.
- Understanding these predictors is crucial for optimizing treatment and preventing complications.
Conclusions:
- Identifying predictors of treatment response is vital for personalized therapy in pediatric SAA.
- Advancements in understanding treatment outcomes for IST and haplo-HSCT can improve patient management.
- This review provides insights to aid clinical decision-making in diverse pediatric SAA scenarios.
Abstract:
Pediatric acquired severe aplastic anemia (SAA), a prevalent non-malignant hematological disorder, presents significant therapeutic challenges and carries considerable risks. Despite substantial progress in immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recent years, the protracted treatment duration, substantial costs, and significant disparities in long-term survival outcomes among patients remain problematic. Identifying predictors of treatment response before therapy initiation is crucial for optimal clinical decision-making and complication prevention. Recent studies has pinpointed predictive factors for IST and haploidentical hematopoietic stem cell transplantation (haplo-HSCT) efficacy in SAA, fostering the development and utilization of transplantation-based scoring systems for prognosis evaluation. This review summarizes advancements in treating pediatric SAA and discusses key elements that influence the outcomes of IST and haplo-HSCT, aiming to support clinical decision-making in diverse clinical scenarios.
